CTX-130
CRISPR Therapeutics AG
[]
crispr therapeutics presents positive results from its phase 1 cobalt -lym trial of ctx130 in relapsed or refractory t cell malignancies at the 2022 european hematology association (eha) congress 
On YouTube ?? #CRISPR & Beyond | $EDIT $BEAM $CRSP $NTLA $VERV $GRPH $CRBU | Join the Discord ??